NFKB1 and breast carcinoma: The primary purpose of the investigation is to determine if CUR reduces NF-kB DNA binding and, ultimately, its downstream mediator IL-6 in patients receiving XRT for their breast cancer after having completed chemotherapy [122] (Figure 1).